Document:

Exhibit
10.1

 

FUBOTV
INC.

 

2020
EQUITY INCENTIVE PLAN, AS AMENDED

 

1.
Purposes of the Plan. The purposes of this Plan are:

 

	 	●	to
    attract and retain the best available personnel for positions of substantial responsibility,
	 	 	 
	 	●	to
    provide additional incentive to Employees, Directors and Consultants, and
	 	 	 
	 	●	to
    promote the success of the Company’s business.

 

The
Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted
Stock Units, Performance Units and Performance Shares.

 

2.
Definitions. As used herein, the following definitions will apply:

 

(a)
“Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with
Section 4 of the Plan.

 

(b)
“Applicable Laws” means the legal and regulatory requirements relating to the administration of equity-based
awards, including but not limited to the related issuance of shares of Common Stock, including but not limited to under U.S. federal
and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the
Common Stock is listed or quoted and the applicable laws of any non-U.S. country or jurisdiction where Awards are, or will be,
granted under the Plan.

 

(c)
“Award” means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights,
Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares.

 

(d)
“Award Agreement” means the written or electronic agreement setting forth the terms and provisions applicable
to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.

 

(e)
“Board” means the Board of Directors of the Company.

 

(f)
“Change in Control” means the occurrence of any of the following events:

 

(i)
Change in Ownership of the Company. A change in the ownership of the Company which occurs on the date that any one person,
or more than one person acting as a group (“Person”), acquires ownership of the stock of the Company that,
together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock
of the Company; provided, however, that for purposes of this subsection, the acquisition of additional stock by any one Person,
who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered
a Change in Control. Further, if the stockholders of the Company immediately before such change in ownership continue to retain
immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company’s
voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more
of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event shall not be
considered a Change in Control under this subsection (i). For this purpose, indirect beneficial ownership shall include, without
limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities
which own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities;
or

 

    	 

     

    

 

(ii)
Change in Effective Control of the Company. A change in the effective control of the Company which occurs on the date that
a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election
is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this
subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control
of the Company by the same Person will not be considered a Change in Control; or

 

(iii)
Change in Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a substantial
portion of the Company’s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12)
month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a
total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets
of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection
(iii), the following will not constitute a change in the ownership of a substantial portion of the Company’s assets: (A)
a transfer to an entity that is controlled by the Company’s stockholders immediately after the transfer, or (B) a transfer
of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with
respect to the Company’s stock, (2) an entity, fifty percent (50%) or more of the total value or voting power of which is
owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of
the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least fifty percent (50%) of
the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3).
For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the
assets being disposed of, determined without regard to any liabilities associated with such assets.

 

For
purposes of this Section 2(f), persons will be considered to be acting as a group if they are owners of a corporation that enters
into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.

 

Notwithstanding
the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event
within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury
Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.

 

    	- 2 -

     

    

 

Further
and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the
jurisdiction of the Company’s incorporation, or (ii) its sole purpose is to create a holding company that will be owned
in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction.

 

(g)
“Code” means the Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or
regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable
provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.

 

(h)
“Committee” means a committee of Directors or of other individuals satisfying Applicable Laws appointed by
the Board, or by a duly authorized committee of the Board, in accordance with Section 4 hereof.

 

(i)
“Common Stock” means the common stock of the Company.

 

(j)
“Company” means fuboTV Inc., a Florida corporation, or any successor thereto.

 

(k)
“Consultant” means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary
to render bona fide services to such entity, provided the services (i) are not in connection with the offer or sale of securities
in a capital-raising transaction, and (ii) do not directly promote or maintain a market for the Company’s securities, in
each case, within the meaning of Form S-8 promulgated under the Securities Act, and provided further, that a Consultant will include
only those persons to whom the issuance of Shares may be registered under Form S-8 promulgated under the Securities Act.

 

(l)
“Director” means a member of the Board.

 

(m)
“Disability” means total and permanent disability as defined in Code Section 22(e)(3), provided that in the
case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total
disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.

 

(n)
“Employee” means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary
of the Company. Neither service as a Director nor payment of a director’s fee by the Company will be sufficient to constitute
“employment” by the Company.

 

(o)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(p)
“Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange
for awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type,
and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other
person or entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Award is reduced or increased.
The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.

 

    	- 3 -

     

    

 

(q)
“Fair Market Value” means, as of any date, the value of Common Stock determined as follows:

 

(i)
If the Common Stock is listed on any established stock exchange or a national market system (other than an over-the counter market,
which will not be considered an established stock exchange of national market system for the purposes of this definition), including
without limitation the New York Stock Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital
Market of The Nasdaq Stock Market, its Fair Market Value will be the closing sales price for such stock (or, if no closing sales
price was reported on that date, as applicable, on the last trading date such closing sales price was reported) as quoted on such
exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator
deems reliable;

 

(ii)
If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market
Value of a Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or,
if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as
reported in The Wall Street Journal or such other source as the Administrator deems reliable;

 

(iii)
In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.

 

(r)
“Fiscal Year” means the fiscal year of the Company.

 

(s)
“Incentive Stock Option” means an Option that by its terms qualifies and is otherwise intended to qualify as
an incentive stock option within the meaning of Code Section 422 and the regulations promulgated thereunder.

 

(t)
“Nonstatutory Stock Option” means an Option that by its terms does not qualify or is not intended to qualify
as an Incentive Stock Option.

 

(u)
“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange
Act and the rules and regulations promulgated thereunder.

 

(v)
“Option” means a stock option granted pursuant to the Plan.

 

(w)
“Outside Director” means a Director who is not an Employee.

 

(x)
“Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Code Section
424(e).

 

    	- 4 -

     

    

 

(y)
“Participant” means the holder of an outstanding Award.

 

(z)
“Performance Share” means an Award denominated in Shares which may be earned in whole or in part upon attainment
of performance goals or other vesting criteria as the Administrator may determine pursuant to Section 10.

 

(aa)
“Performance Unit” means an Award which may be earned in whole or in part upon attainment of performance goals
or other vesting criteria as the Administrator may determine and which may be settled for cash, Shares or other securities or
a combination of the foregoing pursuant to Section 10.

 

(bb)
“Period of Restriction” means the period during which the transfer of Shares of Restricted Stock are subject
to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the
passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.

 

(cc)
“Plan” means this 2020 Equity Incentive Plan.

 

(dd)
“Restricted Stock” means Shares issued pursuant to an Award of Restricted Stock under Section 8 of the Plan,
or issued pursuant to the early exercise of an Option.

 

(ee)
“Restricted Stock Unit” means a bookkeeping entry representing an amount equal to the Fair Market Value of
one Share, granted pursuant to Section 9. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.

 

(ff)
“Rule 16b-3” means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion
is being exercised with respect to the Plan.

 

(gg)
“Section 16(b)” means Section 16(b) of the Exchange Act.

 

(hh)
“Securities Act” means the Securities Act of 1933, as amended.

 

(ii)
“Service Provider” means an Employee, Director or Consultant.

 

(jj)
“Share” means a share of the Common Stock, as adjusted in accordance with Section 15 of the Plan.

 

(kk)
“Stock Appreciation Right” means an Award, granted alone or in connection with an Option, that pursuant to
Section 7 is designated as a Stock Appreciation Right.

 

(ll)
“Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in
Code Section 424(f).

 

3.
Stock Subject to the Plan.

 

(a)
Stock Subject to the Plan. Subject to the provisions of Section 15 of the Plan, the maximum aggregate number of Shares
that may be subject to Awards and sold under the Plan is 31,116,646 Shares. The Shares may be authorized but unissued, or reacquired
Common Stock.

 

    	- 5 -

     

    

 

(b)
Lapsed Awards. If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant
to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares,
is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased Shares (or for Awards other than Options
or Stock Appreciation Rights the forfeited or repurchased Shares) which were subject thereto will become available for future
grant or sale under the Plan (unless the Plan has terminated). With respect to Stock Appreciation Rights, only Shares actually
issued pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock Appreciation
Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated). Shares that have actually
been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution
under the Plan; provided, however, that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock Units, Performance
Shares or Performance Units are repurchased by the Company or are forfeited to the Company due to the failure to vest, such Shares
will become available for future grant under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax
withholdings related to an Award will become available for future grant or sale under the Plan. To the extent an Award under the
Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for
issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in Section 15, the maximum number
of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share number stated in Section
3(a), plus, to the extent allowable under Code Section 422 and the Treasury Regulations promulgated thereunder, any Shares that
become available for issuance under the Plan pursuant to Sections 3(b) and 3(c).

 

(c)
Prior Plan Awards. If any award issued pursuant to the Company’s 2014 Incentive Stock Plan or the 2015 Equity Incentive
Plan of fuboTV Inc. expires or becomes unexercisable without having been exercised in full, is forfeited to or repurchased by
the Company due to the failure to vest, the unpurchased Shares (or for awards other than stock options or stock appreciation rights
the forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan
(unless the Plan has terminated), provided that no more than 11,875,329 Shares may become available under the Plan pursuant to
this Section 3(c).

 

(d)
Share Reserve. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares
as will be sufficient to satisfy the requirements of the Plan.

 

    	- 6 -

     

    

 

4.
Administration of the Plan.

 

(a)
Procedure.

 

(i)
Multiple Administrative Bodies. Different Committees with respect to different groups of Service Providers may administer
the Plan.

 

(ii)
Rule 16b-3. To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated
hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.

 

(iii)
Other Administration. Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee,
which Committee will be constituted to satisfy Applicable Laws.

 

(b)
Powers of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific
duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:

 

(i)
to determine the Fair Market Value;

 

(ii)
to select the Service Providers to whom Awards may be granted hereunder;

 

(iii)
to determine the number of Shares to be covered by each Award granted hereunder;

 

(iv)
to approve forms of Award Agreements for use under the Plan;

 

(v)
to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms
and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may
be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation
regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine;

 

(vi)
to institute and determine the terms and conditions of an Exchange Program;

 

(vii)
to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan;

 

(viii)
to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans
established for the purpose of satisfying applicable non-U.S. laws or for qualifying for favorable tax treatment under applicable
non-U.S. laws;

 

    	- 7 -

     

    

 

(ix)
to modify or amend each Award (subject to Section 20(c) of the Plan), including but not limited to the discretionary authority
to extend the post-termination exercisability period of Awards; provided, however, that in no case will an Option or Stock Appreciation
Right be extended beyond its original maximum term;

 

(x)
to allow Participants to satisfy tax withholding obligations in a manner prescribed in Section 15(d);

 

(xi)
to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously
granted by the Administrator;

 

(xii)
to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such
Participant under an Award; and

 

(xiii)
to make all other determinations deemed necessary or advisable for administering the Plan.

 

(c)
Effect of Administrator’s Decision. The Administrator’s decisions, determinations and interpretations will
be final and binding on all Participants and any other holders of Awards and will be given the maximum deference permitted by
Applicable Laws.

 

5.
Eligibility. Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to any Service
Providers. Nonstatutory Stock Options and Stock Appreciation Rights, to the extent required for exemption under Section 409A,
may be granted only to Service Providers rendering services to the Company or a Subsidiary (not a Parent). Incentive Stock Options
may be granted only to Employees.

 

6.
Stock Options.

 

(a)
Grant of Options. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time,
may grant Options in such amounts as the Administrator, in its sole discretion, will determine.

 

(b)
Option Agreement. Each Award of an Option will be evidenced by an Award Agreement that will specify the exercise price,
the term of the Option, the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option,
and such other terms and conditions as the Administrator, in its sole discretion, will determine.

 

(c)
Limitations. Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory
Stock Option. Notwithstanding such designation, however, to the extent that the aggregate Fair Market Value of the Shares with
respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under
all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated
as Nonstatutory Stock Options. For purposes of this Section 6(c), Incentive Stock Options will be taken into account in the order
in which they were granted, the Fair Market Value of the Shares will be determined as of the time the Option with respect to such
Shares is granted, and the calculation will be performed in accordance with Code Section 422 and Treasury Regulations promulgated
thereunder.

 

    	- 8 -

     

    

 

(d)
Term of Option. The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option,
the term will be no more than ten (10) years from the date of grant thereof. In the case of an Incentive Stock Option granted
to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of
the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive
Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in the Award Agreement.

 

(e)
Option Exercise Price and Consideration.

 

(i)
Exercise Price. The per Share exercise price for the Shares to be issued pursuant to the exercise of an Option will be
determined by the Administrator, subject to the following:

 

(1)
In the case of an Incentive Stock Option

 

a)
granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%)
of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no
less than one hundred ten percent (110%) of the Fair Market Value per Share (or the fair market value per Share as determined
in accordance with Treas. Reg. 1.409A-1(b)(5)(iv)(A)) on the date of grant.

 

b)
granted to any Employee other than an Employee described in paragraph (A) immediately above, the per Share exercise price will
be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.

 

(2)
In the case of a Nonstatutory Stock Option, the per Share exercise price will be no less than one hundred percent (100%) of the
Fair Market Value per Share on the date of grant (or the fair market value per Share as determined in accordance with Treas. Reg.
1.409A-1(b)(5)(iv)(A)).

 

(3)
Notwithstanding the foregoing provisions of this Section 6(e), Options may be granted with a per Share exercise price of less
than one hundred percent (100%) of the Fair Market Value per Share on the date of grant pursuant to a transaction described in,
and in a manner consistent with, Code Section 424(a).

 

(ii)
Waiting Period and Exercise Dates. At the time an Option is granted, the Administrator will fix the period within which
the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.

 

(iii)
Form of Consideration. The Administrator will determine the acceptable form of consideration for exercising an Option,
including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form
of consideration at the time of grant. Such consideration may consist entirely of: (1) cash; (2) check; (3) promissory note; to
the extent permitted by Applicable Laws; (4) other Shares, provided that such Shares have a Fair Market Value on the date of surrender
equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided further that accepting
such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole
discretion; (5) consideration received by the Company under a broker assisted (or other) cashless exercise program (whether through
a broker or otherwise) implemented by the Company in connection with the Plan; (6) by net exercise; (7) such other consideration
and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (8) any combination of the foregoing
methods of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if
acceptance of such consideration may be reasonably expected to benefit the Company.

 

    	- 9 -

     

    

 

(f)
Exercise of Option.

 

(i)
Procedure for Exercise; Rights as a Stockholder. Any Option granted hereunder will be exercisable according to the terms
of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement.
An Option may not be exercised for a fraction of a Share.

 

An
Option will be deemed exercised when the Company receives: (i) notice of exercise (in such form as the Administrator may specify
from time to time) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which
the Option is exercised (together with applicable tax withholding). Full payment may consist of any consideration and method of
payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option
will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her
spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized
transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect
to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued)
such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record
date is prior to the date the Shares are issued, except as provided in Section 15 of the Plan.

 

Exercising
an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under
the Option, by the number of Shares as to which the Option is exercised.

 

(ii)
Termination of Relationship as a Service Provider. If a Participant ceases to be a Service Provider, other than upon the
Participant’s termination as the result of the Participant’s death or Disability, the Participant may exercise his
or her Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the
date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement).
In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3) months following the
Participant’s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant
is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.
If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option
will terminate, and the Shares covered by such Option will revert to the Plan.

 

    	- 10 -

     

    

 

(iii)
Disability of Participant. If a Participant ceases to be a Service Provider as a result of the Participant’s Disability,
the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent
the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth
in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve
(12) months following the Participant’s termination. Unless otherwise provided by the Administrator, if on the date of termination
the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert
to the Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option
will terminate, and the Shares covered by such Option will revert to the Plan.

 

(iv)
Death of Participant. If a Participant dies while a Service Provider, the Option may be exercised following the Participant’s
death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of
death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award
Agreement), by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to Participant’s
death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option
may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option is transferred
pursuant to the Participant’s will or in accordance with the laws of descent and distribution. In the absence of a specified
time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant’s death. Unless
otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the
Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within
the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.

 

7.
Stock Appreciation Rights.

 

(a)
Grant of Stock Appreciation Rights. Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be
granted to Service Providers of the Company or a Subsidiary at any time and from time to time as will be determined by the Administrator,
in its sole discretion.

 

(b)
Number of Shares. The Administrator will have complete discretion to determine the number of Shares subject to any Award
of Stock Appreciation Rights.

 

(c)
Exercise Price and Other Terms. The per Share exercise price for the Shares that will determine the amount of the payment
to be received upon exercise of a Stock Appreciation Right as set forth in Section 7(f) will be determined by the Administrator
and will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator,
subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation
Rights granted under the Plan.

 

(d)
Stock Appreciation Right Agreement. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will
specify the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions
as the Administrator, in its sole discretion, will determine.

 

    	- 11 -

     

    

 

(e)
Expiration of Stock Appreciation Rights. A Stock Appreciation Right granted under the Plan will expire upon the date determined
by the Administrator, in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of
Section 6(d) relating to the maximum term and Section 6(f) relating to exercise also will apply to Stock Appreciation Rights.

 

(f)
Payment of Stock Appreciation Right Amount. Upon exercise of a Stock Appreciation Right, a Participant will be entitled
to receive payment from the Company in an amount determined by multiplying:

 

(i)
The difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times

 

(ii)
The number of Shares with respect to which the Stock Appreciation Right is exercised.

 

At
the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent
value, or in some combination thereof.

 

8.
Restricted Stock.

 

(a)
Grant of Restricted Stock. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time
to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion,
will determine.

 

(b)
Restricted Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the
Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion,
will determine. Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock
until the restrictions on such Shares have lapsed.

 

(c)
Transferability. Except as provided in this Section 8 or as the Administrator determines, Shares of Restricted Stock may
not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of
Restriction.

 

(d)
Other Restrictions. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted
Stock as it may deem advisable or appropriate.

 

(e)
Removal of Restrictions. Except as otherwise provided in this Section 8, Shares of Restricted Stock covered by each Restricted
Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction
or at such other time as the Administrator may determine. The Administrator, in its discretion, may accelerate the time at which
any restrictions will lapse or be removed.

 

    	- 12 -

     

    

 

(f)
Voting Rights. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder
may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.

 

(g)
Dividends and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock
will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides
otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability
and forfeitability as the Shares of Restricted Stock with respect to which they were paid.

 

(h)
Return of Restricted Stock to Company. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions
have not lapsed will revert to the Company and again will become available for grant under the Plan.

 

9.
Restricted Stock Units.

 

(a)
Grant. Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After
the Administrator determines that it will grant Restricted Stock Units under the Plan, it will advise the Participant in an Award
Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units.

 

(b)
Vesting Criteria and Other Terms. The Administrator will set vesting criteria in its discretion, which, depending on the
extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant.
The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual
goals (including, but not limited to, continued employment or service), applicable federal or state securities laws, or any other
basis determined by the Administrator in its discretion.

 

(c)
Earning Restricted Stock Units. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive
a payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units,
the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.

 

(d)
Form and Timing of Payment. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s)
determined by the Administrator and set forth in the Award Agreement which shall establish exemption or comply with all requirements
of Code Section 409A. The Administrator, in its sole discretion, may settle earned Restricted Stock Units in cash, Shares, or
a combination of both.

 

(e)
Cancellation. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the
Company.

 

    	- 13 -

     

    

 

10.
Performance Units and Performance Shares.

 

(a)
Grant of Performance Units/Shares. Performance Units and Performance Shares may be granted to Service Providers at any
time and from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete
discretion in determining the number of Performance Units and Performance Shares granted to each Participant.

 

(b)
Value of Performance Units/Shares. Each Performance Unit will have an initial value that is established by the Administrator
on or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on
the date of grant.

 

(c)
Performance Objectives and Other Terms. The Administrator will set performance objectives or other vesting provisions (including,
without limitation, continued status as a Service Provider) in its discretion which, depending on the extent to which they are
met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. The time period
during which the performance objectives or other vesting provisions must be met will be called the “Performance Period.”
Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such
other terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set performance
objectives based upon the achievement of Company-wide, divisional, business unit or individual goals (including, but not limited
to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator
in its discretion.

 

(d)
Earning of Performance Units/Shares. After the applicable Performance Period has ended, the holder of Performance Units/Shares
will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance
Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions
have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive
any performance objectives or other vesting provisions for such Performance Unit/Share.

 

(e)
Form and Timing of Payment of Performance Units/Shares. Payment of earned Performance Units/Shares will be made as soon
as practicable after the expiration of the applicable Performance Period or at such other time as may be specified in the Award
Agreement which shall establish exemption or comply with all requirements of Code Section 409A. The Administrator, in its sole
discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value
equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination
thereof.

 

(f)
Cancellation of Performance Units/Shares. On the date set forth in the Award Agreement, all unearned or unvested Performance
Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan.

 

    	- 14 -

     

    

 

11.
Outside Director Limitations. No Outside Director may be granted, in any Fiscal Year, Awards with a grant date fair value
(determined in accordance with U.S. generally accepted accounting principles) of more than $750,000, increased to $1,500,000 in
connection with his or her initial service. Any Awards granted to an individual while he or she was an Employee, or while he or
she was a Consultant but not an Outside Director, will not count for purposes of the limitations under this Section 11.

 

12.
Compliance With Code Section 409A. Awards will be designed and operated in such a manner that they are either exempt from
the application of, or comply with, the requirements of Code Section 409A such that the grant, payment, settlement or deferral
will not be subject to the additional tax or interest applicable under Code Section 409A, except as otherwise determined in the
sole discretion of the Administrator. The Plan and each Award Agreement under the Plan is intended to meet the requirements of
Code Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the
sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject
to Code Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code
Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable
under Code Section 409A. In no event will the Company have any obligation under the terms of this Plan to reimburse a Participant
for any taxes or other costs that may be imposed on Participant as a result of Section 409A.

 

13.
Leaves of Absence/Transfer Between Locations. Unless the Administrator provides otherwise, vesting of Awards granted hereunder
will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i) any leave
of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any
Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration
of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company
is not so guaranteed, then six (6) months following the first (1st) day of such leave, any Incentive Stock Option held
by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory
Stock Option.

 

14.
Limited Transferability of Awards.

 

Unless
determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, or otherwise transferred in
any manner other than by will or by the laws of descent and distribution, and may be exercised, during the lifetime of the Participant,
only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions
as the Administrator deems appropriate.

 

15.
Adjustments; Dissolution or Liquidation; Merger or Change in Control.

 

(a)
Adjustments. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities,
or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off,
combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure
of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or
potential benefits intended to be made available under the Plan, will adjust the number and class of shares of stock that may
be delivered under the Plan and/or the number, class, and price of shares of stock covered by each outstanding Award, and the
numerical Share limits of Section 3.

 

    	- 15 -

     

    

 

(b)
Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator will
notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has
not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.

 

(c)
Change in Control. In the event of a merger of the Company with or into another corporation or other entity or a Change
in Control, each outstanding Award will be treated as the Administrator determines (subject to the provisions of the following
paragraph) without a Participant’s consent, including, without limitation, that (i) Awards will be assumed, or substantially
equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments
as to the number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant’s Awards
will terminate upon or immediately prior to the consummation of such merger or Change in Control; (iii) outstanding Awards will
vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part prior
to or upon consummation of such merger or Change in Control, and, to the extent the Administrator determines, terminate upon or
immediately prior to the effectiveness of such merger or Change in Control; (iv) (A) the termination of an Award in exchange for
an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Award or
realization of the Participant’s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt,
if as of the date of the occurrence of the transaction the Administrator determines in good faith that no amount would have been
attained upon the exercise of such Award or realization of the Participant’s rights, then such Award may be terminated by
the Company without payment), or (B) the replacement of such Award with other rights or property selected by the Administrator
in its sole discretion; or (v) any combination of the foregoing. In taking any of the actions permitted under this subsection
15(c), the Administrator will not be obligated to treat all Awards, all Awards held by a Participant, or all Awards of the same
type, similarly.

 

In
the event that the successor corporation does not assume or substitute for the Award (or portion thereof), the Participant will
fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares
as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock
Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria
will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, in all cases, unless
specifically provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the
Company or any of its Subsidiaries or Parents, as applicable. In addition, if an Option or Stock Appreciation Right is not assumed
or substituted in the event of a merger or Change in Control, the Administrator will notify the Participant in writing or electronically
that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole
discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of such period.

 

    	- 16 -

     

    

 

For
the purposes of this subsection 15(c) and subsection 15(d), an Award will be considered assumed if, following the merger or Change
in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the merger
or Change in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change
in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered
a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided,
however, that if such consideration received in the merger or Change in Control is not solely common stock of the successor corporation
or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received
upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, Performance Unit, or
Performance Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent
equal in fair market value to the per share consideration received by holders of Common Stock in the merger or Change in Control.

 

Notwithstanding
anything in this Section 15(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more
performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without
the Participant’s consent, in all cases, unless specifically provided otherwise under the applicable Award Agreement or
other written agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable; provided,
however, a modification to such performance goals only to reflect the successor corporation’s post-Change in Control corporate
structure will not be deemed to invalidate an otherwise valid Award assumption.

 

Notwithstanding
anything in this Section 15(c) to the contrary, and unless otherwise provided in an Award Agreement, if an Award that vests, is
earned or paid-out under an Award Agreement is subject to Code Section 409A and if the change in control definition contained
in the Award Agreement does not comply with the definition of “change of control” for purposes of a distribution under
Code Section 409A, then any payment of an amount that is otherwise accelerated under this Section will be delayed until the earliest
time that such payment would be permissible under Code Section 409A without triggering any penalties applicable under Code Section
409A.

 

(d)
Outside Director Awards. In the event of a Change in Control, with respect to Awards granted to an Outside Director, the
Outside Directors will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the
Shares underlying such Award, including those Shares which would not otherwise be vested or exercisable, all restrictions on Restricted
Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals
or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions
met, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the Participant
and the Company or any of its Subsidiaries or Parents, as applicable.

 

    	- 17 -

     

    

 

16.
Tax Withholding.

 

(a)
Withholding Requirements. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such
earlier time as any tax withholding obligation is due, the Company will have the power and the right to deduct or withhold, or
require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, non-U.S. or other taxes
(including the Participant’s FICA obligation) required to be withheld with respect to such Award (or exercise thereof).

 

(b)
Withholding Arrangements. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from
time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by such methods as the
Administrator shall determine, including, without limitation, (i) paying cash, (ii) electing to have the Company withhold otherwise
deliverable cash or Shares having a fair market value equal to the minimum statutory amount required to be withheld or such greater
amount as the Administrator may determine if such amount would not have adverse accounting consequences, as the Administrator
determines in its sole discretion, (iii) delivering to the Company already-owned Shares having a fair market value equal to the
minimum statutory amount required to be withheld or such greater amount as the Administrator may determine, in each case, provided
the delivery of such Shares will not result in any adverse accounting consequences, as the Administrator determines in its sole
discretion, (iv) selling a sufficient number of Shares otherwise deliverable to the Participant through such means as the Administrator
may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld, or (v)
any combination of the foregoing methods of payment. The amount of the withholding requirement will be deemed to include any amount
which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using
the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date
that the amount of tax to be withheld is to be determined or such greater amount as the Administrator may determine if such amount
would not have adverse accounting consequences, as the Administrator determines in its sole discretion. The fair market value
of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.

 

17.
No Effect on Employment or Service. Neither the Plan nor any Award will confer upon a Participant any right with respect
to continuing the Participant’s relationship as a Service Provider with the Company or its Subsidiaries or Parents, as applicable,
nor will they interfere in any way with the Participant’s right or the right of the Company and its Subsidiaries or Parents,
as applicable to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.

 

18.
Date of Grant. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination
granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided
to each Participant within a reasonable time after the date of such grant.

 

19.
Term of Plan. The Plan will become effective upon its adoption by the Board. It will continue in effect for a term of ten
(10) years from the date adopted by the Board, unless terminated earlier under Section 20 of the Plan.

 

    	- 18 -

     

    

 

20.
Amendment and Termination of the Plan.

 

(a)
Amendment and Termination. The Administrator may at any time amend, alter, suspend or terminate the Plan.

 

(b)
Stockholder Approval. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable
to comply with Applicable Laws.

 

(c)
Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan will impair the rights
of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in
writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator’s ability
to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.

 

21.
Conditions Upon Issuance of Shares.

 

(a)
Legal Compliance. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and
the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel
for the Company with respect to such compliance.

 

(b)
Investment Representations. As a condition to the exercise of an Award, the Company may require the person exercising such
Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without
any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is
required.

 

22.
Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction
or to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal
or non-U.S. law or under the rules and regulations of the Securities and Exchange Commission, the stock exchange on which Shares
of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification
or rule compliance is deemed by the Company’s counsel to be necessary or advisable for the issuance and sale of any Shares
hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite
authority, registration, qualification or rule compliance will not have been obtained.

 

23.
Stockholder Approval. The Plan will be presented for approval by the stockholders of the Company within twelve (12) months
after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required
under Applicable Laws. No Option granted under the Plan may be treated as an Incentive Stock Option is the Plan is not approved
by stockholders of the Company within twelve (12) months after the date the Plan is adopted by the Board.

 

    	- 19 -

     

    

 

24.
Forfeiture Events.

 

(a)
All Awards under the Plan will be subject to recoupment under any clawback policy that the Company is required to adopt pursuant
to the listing standards of any national securities exchange or association on which the Company’s securities are listed
or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Laws. In addition,
the Administrator may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Administrator
determines necessary or appropriate, including but not limited to a reacquisition right regarding previously acquired Shares or
other cash or property. Unless this Section 24 is specifically mentioned and waived in an Award Agreement or other document, no
recovery of compensation under a clawback policy or otherwise will be an event that triggers or contributes to any right of a
Participant to resign for “good reason” or “constructive termination” (or similar term) under any agreement
with the Company or a Subsidiary or Parent of the Company.

 

(b)
The Administrator may specify in an Award Agreement that the Participant’s rights, payments, and benefits with respect to
an Award will be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition
to any otherwise applicable vesting or performance conditions of an Award. Such events may include, but will not be limited to,
termination of such Participant’s status as Service Provider for cause or any specified action or inaction by a Participant,
whether before or after such termination of service, that would constitute cause for termination of such Participant’s status
as a Service Provider.

 

    	- 20 -EX-10.10

 Exhibit 10.10 

COLLABORATION AGREEMENT 

This Collaboration Agreement (this “Agreement”), dated January 21, 2019 (the “Effective Date”), is by and between
RePharmation Inc., a Delaware corporation (“Customer”), RePharmation Limited, a Bermuda company (“Limited”), and SPARCBIO LLC, a Delaware limited liability company (“Consultant”). 

RECITALS 

Customer and GIRAFPHARMA LLC, an Affiliate (as defined in the AAA) of Consultant, are parties to that certain Asset Acquisition Agreement,
dated January 21, 2019 (the “AAA”), pursuant to which Customer will acquire certain programs from GIRAFPHARMA LLC (the “Acquired Programs”) at the Closing (as defined in the AAA, the
“Closing”). 
 Limited, an affiliate of Customer, and Consultant are parties to that certain Master Services Agreement,
dated April 24, 2018 (the “MSA”), pursuant to which Consultant is providing certain research and development services to Limited related to certain programs other than the Acquired Programs (the “MSA
Programs”). 
 Customer and Consultant may expand the Services under this Agreement as provided below to include certain Other
Programs (as defined in Section 2.1 below) (together, the Other Programs, Acquired Programs and MSA Programs, the “Programs”). 

Customer, Limited and Consultant now desire that Consultant provide research and development services to Customer for the Programs under the
terms of this Agreement, and that the services previously conducted under the MSA, which will be terminated, now be conducted under this Agreement. 

AGREEMENT 

The parties to this Agreement, intending to be legally bound, agree as follows: 

 

	1.	 TERMINATION OF MSA 

Limited, Customer and Consultant agree that: (a) the MSA is hereby terminated by mutual agreement as of the Effective Date, (b) all Proprietary
Information (as defined in the MSA) will be deemed Proprietary Information under this Agreement, (c) notwithstanding Section 5.4 of the MSA, Consultant may retain property of Limited in Consultant’s possession solely for use in
conducting the Services under this Agreement, and (d) Sections 3, 4 and 7-10 of the MSA will survive termination thereof. Within thirty (30) days after the Effective Date, Consultant shall invoice
Limited for any remaining payments due under the MSA (if any), provided that any fixed monthly payments will be prorated based on when in the month the Effective Date occurs. 
  

	2.	 SERVICES 

2.1 Statements of Work. Customer may from time to time issue statement(s) of work (each, a “Statement of Work”).
Each Statement of Work shall be subject to all of the terms and conditions contained in this Agreement, shall become binding upon execution by Customer and Consultant and, upon execution, is hereby incorporated into this Agreement by reference. If
at any time Customer desires Consultant to conduct services with respect to any new program, Customer may notify Consultant, and Customer and Consultant will thereafter discuss services for such new program in good faith. Provided that such services
are within the expertise of Consultant or its subcontractors, and that the number of FTEs 

  
 1 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
specified in all Statements of Work then in effect may be re-allocated to include such new program, Customer and Consultant will amend the applicable
Statement(s) of Work, or enter into a new Statement of Work, to include activities for such new program (each, an “Other Program”); provided, further that such Other Programs will not include any programs that the Consultant has
(i) entered into a bona fide final term sheet or contract with a third party specifically related to the molecular target of the proposed program, or (ii) initiated, and incurred material expenses with respect to, an internal program
targeting the same molecular target as the proposed program. 
 2.2 Standards. Consultant shall render to Customer those
services set forth in the Statement(s) of Work (“Services”) in a timely and professional manner consistent with industry standards, and in accordance with all applicable laws and regulations, this Agreement and any terms set forth
in the applicable Statement(s) of Work. Consultant may subcontract or otherwise delegate its obligations under this Agreement without Customer’s prior written consent, provided that Consultant will remain liable for any such subcontracted or
delegated obligations. Consultant shall devote the number of FTEs (of Customer or its subcontractors, as applicable) to the Services as specified in each Statement of Work, where each FTE is equivalent to 160 hours of Services per month. Subject to
compliance with Consultant’s obligations hereunder, Consultant shall retain the sole control and discretion to determine the methods by which Consultant performs the Services and the places at which, the equipment and supplies with which, and
the hours during which such Services are to be rendered. Customer reserves the right to reasonably request that Consultant: (i) limit the use of any employee or contractor, (ii) use a particular employee or contractor to conduct certain
Services, or (iii) remove any employee or contractor already engaged in the performance of the Services, provided that (A) Consultant and Customer shall discuss any such requests and Consultant shall have a reasonable time period to
address any concerns raised by Customer with respect to such employees or contractors and (B) if Consultant does not address Customer’s reasonable concerns within such reasonable time period, then Consultant shall take the requested
actions. Customer’s exercise of such right shall in no way be construed as relieving Consultant from its obligations under this Agreement. 
  

	3.	 PAYMENTS 

3.1 Compensation. In consideration of the Services to be rendered pursuant to each Statement of Work in accordance with the terms
of this Agreement, Consultant shall be paid as set forth in the applicable Statement of Work in accordance with the budget therein and this Section 3.1. Unless otherwise agreed by Consultant and Customer, Consultant will provide a rolling
forecast on a calendar quarterly basis for the amounts due for Services in the following four (4) calendar quarters in accordance with the budget in the applicable Statement of Work. An initial forecast (for January 2019 through
December 31, 2019) will be provided within ten (10) days after the Effective Date. Subsequent forecasts will be due on March 15, June 15, September 15 and December 15 of each year. Consultant will include with such
forecast an invoice for the greater of: (i) the amounts forecast for the Services to be performed in the subsequent calendar quarter (or, in the case of the first payment, for the period from the Effective Date through March 31, 2019) and
(ii) [***]. Within ten (10) days after the end of each calendar quarter, Consultant shall provide Customer with a reasonably detailed statement of all costs incurred by Consultant to conduct the Services in such calendar quarter in
accordance with the budget in the applicable Statement of Work (the “Actual Costs”), including reasonable documentation for any third party costs, and will include in the subsequent invoice to Customer any Actual Costs for Services
in such calendar quarter in excess of the advance payment made by Customer for such calendar quarter. Customer will pay all invoiced amounts due under this Section 3.1 within thirty (30) days from receipt by Customer of Consultant’s
invoice therefor, unless subject to a bona fide dispute. If the advance payment by Customer for any calendar quarter exceeds the Actual Costs for such calendar quarter, then Consultant will credit any excess to the amount invoiced for the subsequent
calendar quarter (or if there is no such invoice, will refund such excess to Customer within thirty (30) days), and Customer’s prepayment 

  
 2 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
obligation for such subsequent calendar quarter will be reduced by the amount of such overpayment, provided that the total payment for Services performed to Customer’s reasonable
satisfaction under each calendar year of this Agreement will be at least [***] per year (which includes [***] FTE costs of Consultant and [***] of chemistry CRO costs). For clarity, except for a termination of this Agreement by Customer pursuant to
Section 6.2(a) or Consultant pursuant to Section 6.2(a) or a termination of this Agreement pursuant to Section 6.2(b), Customer shall be obligated to pay to Consultant the [***] per year for the entire term of the Agreement. 

3.2 Expenses. Customer shall reimburse Consultant for reasonable travel and other business expenses that are incurred by
Consultant in the performance of the Services and are approved in advance by Customer, in accordance with Customer’s general policies, as may be amended from time to time. Consultant shall provide Customer with an itemized list of all such
expenses and supporting receipts with each invoice therefor. 
 3.3 Taxes. Consultant acknowledges and agrees that it shall be
Consultant’s obligation to report as income all compensation received by Consultant pursuant to this Agreement and to pay any withholding taxes, self-employment taxes, and social security, unemployment or disability insurance or similar items,
including interest and penalties thereon, in connection with any payments made to Consultant by Customer pursuant to this Agreement, including any Statement of Work. Consultant agrees to indemnify, hold harmless and, at Customer’s discretion,
defend Customer against any and all liability related thereto, including, without limitation, any taxes, penalties and interest Customer may be required to pay as a result of Consultant’s failure to report such compensation or make such
payments. 
  

	4.	 PROPRIETARY INFORMATION 

4.1 Proprietary Information. Consultant understands that its work for Customer will involve access to and creation of
confidential, proprietary and trade secret information and materials of Customer (or its affiliates, licensors, suppliers, vendors or customers) (collectively, “Proprietary Information”). Proprietary Information includes, without
limitation, any (a) information, ideas or materials of a technical or creative nature, such as research and development results, designs and specifications, computer source and object code, patent applications, and other materials and concepts
relating to Customer’s products, services, processes, technology or other intellectual property rights, including those related to the Programs; (b) all personal property, including, without limitation, all books, manuals, records,
reports, notes, contracts, lists, blueprints and other documents or materials, or copies thereof, received by Consultant in the course of Consultant’s rendering of Services to Customer, (c) all records and any other materials pertaining to
Creations (as defined below) or to the Programs; and (d) the terms and conditions of this Agreement, including all Statements of Work. 

4.2 Restrictions on Use and Disclosure. Consultant understands that Proprietary Information is extremely valuable to Customer and its
affiliates, licensors, suppliers, vendors and customers. Accordingly, Consultant agrees during the term of this Agreement and for a period of seven (7) years thereafter that it (a) shall hold all Proprietary Information in confidence and
trust for the benefit of Customer; (b) shall not copy or use (or allow any of its employees, contractors or agents to copy or use) any Proprietary Information, except as may be necessary to perform the Services, and shall disclose Proprietary
Information to its employees, contractors or agents only on a need-to-know basis; (c) shall use the Proprietary Information only for the benefit of Customer (and
not for the benefit of Consultant or any third party); and (d) shall not disclose or otherwise make available any such Proprietary Information to any third party except as authorized in writing and in advance by Customer. Subject to
Section 5.2, all Proprietary Information is and shall remain the sole property of Customer. 

  
 3 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 4.3 Exclusions. The foregoing restrictions on use and disclosure shall not
apply to any Proprietary Information to the extent Consultant can prove such Proprietary Information (a) is or has become generally known to the public through no unlawful act of Consultant; (b) was known to Consultant at the time of its
disclosure by Customer, as evidenced by Consultant’s written records; (c) was independently developed by Consultant without any use of the Proprietary Information, as evidenced by Consultant’s written records; (d) becomes known
to Consultant from a source other than Customer without breach of this Agreement and otherwise not in violation of Customer’s rights, as evidenced by Consultant’s written records; or (e) such disclosure is approved in advance and in
writing by Customer; provided that the foregoing exceptions (b)-(d) will not apply to Proprietary Information related to the Programs. Notwithstanding Section 4.2, Consultant shall have the right to disclose Proprietary Information to the
extent legally compelled, provided that Consultant shall give advance notice of such compelled disclosure to Customer, and shall cooperate with Customer in connection with any efforts to prevent or limit the scope of such disclosure and/or use of
the Proprietary Information. 
  

	5.	 CREATIONS 

5.1 Definition. As used herein, “Creations” shall include, without limitation, all designs, copyrightable works,
ideas, inventions, technology and other creations, and any related work-in-progress, improvements or modifications to the foregoing, that are created, developed or
conceived (alone or with others) (a) in connection with Consultant’s Services for Customer during the term of this Agreement, whether or not created, developed or conceived during regular business hours, and (b) if based on
Proprietary Information, after termination of this Agreement. Creations shall include, without limitation, all materials delivered to Customer in connection with this Agreement. 

5.2 Assignment. Prior to the Closing, all Creations arising from the Acquired Programs shall be the sole property of Consultant,
provided that such Creations shall be subject to Section 4, except that prior to the Closing, Consultant will have the right to file patent applications disclosing or claiming such Creations arising from the Acquired Programs, provided that
Consultant: (A) promptly provides Customer with drafts of all proposed filings and correspondence to any patent authorities with respect to such Creations or the Acquired Programs for Customer’s review and comment prior to the submission
of such proposed filing or correspondence and (B) confers with Customer and takes into consideration Customer’s reasonable comments prior to submitting such filing or correspondence. Upon Closing, with respect to Creations arising
from the Acquired Programs prior to Closing, and from and after the Effective Date, with respect to all other Creations, all Creations shall be the sole property of Customer, with Customer having the right to obtain and hold in its own name all
intellectual property rights in and to such Creations as of the applicable date. Consultant hereby irrevocably assigns and agrees to assign to Customer, without additional consideration, all right, title and interest in and to all Creations, whether
currently existing or created or developed later, including, without limitation, all copyrights, trademarks, trade secrets, patents, industrial rights and all other intellectual property and proprietary rights related thereto, whether existing now
or in the future, effective (i) upon Closing with respect to Creations arising from the Acquired Programs prior to Closing and (ii) with respect to all other Creations, including Creations arising from the MSA Programs and Other Programs,
immediately upon the inception, conception, creation or development thereof. Consultant shall (a) disclose promptly to Customer all Creations, and (b) whether during or after the period of its consulting arrangement with Customer, execute
such written instruments and do such other acts as may be necessary in the opinion of Customer to obtain a patent, register a copyright or otherwise evidence or enforce Customer’s rights in and to such Creations (and Consultant hereby
irrevocably appoints Customer and any of its officers as its attorney in fact to undertake such acts in its name). 
 5.3
License. To the extent, if any, that Consultant retains any right, title or interest in or to any Creations, then Consultant hereby grants to the Customer a perpetual, irrevocable, fully paid-up,

  
 4 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
transferable, sublicensable, exclusive, worldwide right and license (a) to use, reproduce, distribute, display and perform (whether publicly or otherwise), prepare derivative works of and
otherwise modify, make, sell, offer to sell, import and otherwise use and exploit (and have others exercise such rights on behalf of Customer) all or any portion of such Creations, in any form or media (now known or later developed); (b) to modify
all or any portion of such Creations, including, without limitation, the making of additions to or deletions from such Creations, regardless of the medium (now or hereafter known) into which such Creations may be modified and regardless of the
effect of such modifications on the integrity of such Creations; and (c) to identify Consultant, or not to identify Consultant, as one or more authors of or contributors to such Creations or any portion thereof, whether or not such Creations or
any portion thereof have been modified. Consultant further waives any “moral” rights or other rights with respect to attribution of authorship or integrity of such Creations Consultant may have under any applicable law, whether
under copyright, trademark, unfair competition, defamation, right of privacy, contract, tort or other legal theory. The foregoing rights and licenses in this Section 5.3 will be effective (i) on the Closing with respect to Creations
arising from the Acquired Programs, and (ii) on the Effective Date with respect to all other Creations, including the Creations arising from the MSA Programs and Other Programs. 

 

	6.	 TERM AND TERMINATION 

6.1 Term. This Agreement shall commence on the Effective Date and remain in full force and effect for a period of five
(5) years, unless terminated earlier pursuant to Section 6.2. 
 6.2 Termination. 

(a) Either Customer or Consultant may terminate this Agreement for the other party’s material breach if such breach remains
uncured for thirty (30) days after receipt by the breaching party of written notice thereof. Customer may terminate this Agreement at any time, with or without cause, without further obligation to Consultant, upon thirty (30) days’
notice to Consultant, provided that such termination will be effective no earlier than the third (3rd) anniversary of the Effective Date. 

(b) If the AAA is terminated prior to Closing, then (i) this Agreement will terminate at the same time as the AAA and
(ii) all Creations arising from the Acquired Programs will no longer be considered Proprietary Information. 
 (c)
Notwithstanding the foregoing in Section 6.2(a), if (i) Consultant alleges by written notice to Customer that Customer has breached this Agreement by failing to pay any amounts due under Section 3.1 and (ii) Customer disputes in
good faith the existence of such breach and provides written notice of such dispute to Consultant within the thirty (30)-day cure period, then (A) such dispute shall be settled by binding arbitration
under the Commercial Arbitration Rules (including the rules for expedited procedures) of the American Arbitration Association; (B) Consultant shall not have the right to terminate this Agreement under Section 6.2(a) unless and until
(1) the arbitrator has determined in its award that Customer failed to pay such unpaid amount and (2) Customer fails to pay such amount (together with interest thereon at 12% per annum from the date such amount was originally due under
Section 3.1 through the date such amount is actually paid by Customer) within five (5) business days following such award. It is understood and agreed that during the pendency of such good faith dispute, all of the terms and conditions of
this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder; provided, however, that (i) Customer shall be obligated to pay all amounts due under this Agreement to the extent
that such amounts are not disputed in good faith by Customer; and (ii) during the period in which there is a disputed amount, as long as Consultant continues performing the Services, in no event shall Customer pay to Consultant an amount that
is less than [***] per month (regardless of the amount in dispute). The prevailing party in any such arbitration proceeding shall be entitled to the 

  
 5 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
payment of reasonable attorneys’ fees and costs in connection with such proceeding. For the avoidance of doubt, Consultant may terminate this Agreement if Customer fails to pay amounts due
under this Agreement within the applicable 30-day cure period to the extent such amounts are not in good faith dispute by Customer. 

6.3 Effect of Termination. Upon termination of this Agreement, Consultant shall immediately cease performing the Services. If
this Agreement is terminated by Customer without cause, Customer agrees to pay Consultant the compensation due for the period up to the effective date of termination. If Consultant terminates this Agreement pursuant to Section 6.2(a) (subject
to Section 6.2(c)) prior to the third (3rd) anniversary of the Effective Date on account of Customer’s material breach of this Agreement, then Customer shall remain obligated to pay to
Consultant [***] for each of the first three (3) years of the term of this Agreement, to the extent not already paid to Consultant under Section 3.1. If this Agreement is terminated pursuant to Section 6.2(b), then within thirty
(30) days after such termination Consultant will, with respect to any amounts advanced by Customer under Section 3.1 for Services not conducted prior to termination, at Consultant’s election, either (or both, in any proportion): (a)
refund such amounts to Customer or (b) issue to Customer a SAFE on the same terms as issued to other investors of Consultant. Sections 4, 5, 6.3, 6.4 and 8-11 shall survive termination of this Agreement.

 6.4 Delivery of Customer Property. Upon termination of this Agreement, or at any time Customer so requests, Consultant
shall deliver immediately to Customer all property belonging to Customer, whether given to Consultant by Customer or prepared by Consultant in the course of rendering the Services, including all Creations then in progress and all material in
Consultant’s possession containing Proprietary Information and any copies thereof, whether prepared by Consultant or others. Following termination, Consultant shall not retain any written or other tangible (including machine-readable) material
containing any Proprietary Information. 
  

	7.	 CONFIDENTIAL INFORMATION OF OTHERS

 Consultant shall not breach any agreements to keep in confidence, or to refrain from using, the confidential, proprietary or trade
secret information of another client or employer. Consultant shall not provide to Customer any information of another client or employer, in the Creations or otherwise, nor shall Consultant use any such information in its activities for Customer,
without the prior written consent of Customer and such other client or employer. 
  

	8.	 WARRANTIES 

Consultant represents, warrants and covenants that (a) Consultant has the full power and authority to enter into this Agreement and to perform its
obligations hereunder, without the need for any consents, approvals or immunities not yet obtained; (b) Consultant has the right to grant the rights and assignments granted herein, without the need for any assignments, releases, consents,
approvals, immunities or other rights not yet obtained; (c) the Services, including, without limitation, any deliverables required hereunder, shall be free from material errors or other defects and shall substantially conform to any
specifications for such Services and/or deliverables as set forth or referenced in any applicable Statement of Work; (d) the Creations (and the exercise of the rights granted herein with respect thereto) do not and shall not infringe,
misappropriate or violate any patent, copyright, trademark, trade secret, publicity, privacy or other rights of any third party, and are not and shall not be defamatory or obscene; (e) neither the Creations nor any element thereof shall be
subject to any restrictions or to any mortgages, liens, pledges, security interests, encumbrances or encroachments; and (f) each of Consultant’s employees and contractors (if any) involved in the development of the Creations or who have
access to Proprietary Information have executed (or, prior to any such involvement shall execute) a written agreement with Consultant in which such persons (i) assign 

  
 6 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
to Consultant all right, title and interest in and to the Creations in order that Consultant may fully grant the rights to Customer as provided herein and (ii) agree to be bound by
confidentiality and non-disclosure obligations equivalent to those set forth in this Agreement. Customer hereby disclaims all warranties of any kind, whether express, implied, statutory or otherwise, with
respect to any Proprietary Information or other information or materials supplied by Customer to Consultant hereunder, including, without limitation, any warranties with respect to any specifications for the Creations or other deliverables required
hereunder. 
  

	9.	 INDEMNIFICATION 

9.1 Consultant shall indemnify, defend and hold harmless Customer and its affiliates, successors and assigns (and its and their
officers, directors, employees, (sub)licensees, customers and agents) from and against any and all claims, losses, liabilities, damages, settlements, expenses and costs (including, without limitation, attorneys’ fees and court costs) which
arise out of or relate to any third party claim or threat thereof (a) that the Services or Creations (or the exercise of the rights granted herein with respect thereto) infringe, misappropriate or violate any patent, copyright, trademark, trade
secret, publicity, privacy or other rights of any third party, or are defamatory or obscene, or (b) to the extent arising out of Consultant’s breach of this Agreement or the negligence or willful misconduct of Consultant or its or its
affiliates’ officers, directors, employees and agents. 
 9.2 Customer shall indemnify, defend and hold harmless Consultant and
its affiliates, successors and assigns (and its and their officers, directors, employees, (sub)licensees, customers and agents) from and against any and all claims, losses, liabilities, damages, settlements, expenses and costs (including, without
limitation, attorneys’ fees and court costs) which arise out of or relate to any third party claim or threat thereof to the extent arising out of (a) Customer’s manufacture, use or sale of any products developed using the Creations
(but not the manufacture, use or sale by or on behalf of Consultant), including, without limitation, any product liability claims, except to the extent arising out of Consultant’s breach of this Agreement or the negligence or willful misconduct
of Consultant or its or its affiliates’ officers, directors, employees and agents, or (b) Customer’s breach of this Agreement or the negligence or willful misconduct of Customer or its or its affiliates’ officers, directors,
employees and agents. 
 9.3 Each party’s agreement to indemnify, defend and hold harmless the other party is conditioned on the
indemnified party: (i) providing written notice to the indemnifying party of any claim for which is it seeking indemnification hereunder promptly after the indemnified party has knowledge of such claim; (ii) permitting the indemnifying
party to assume full responsibility to investigate, prepare for and defend against any such claim, except that the indemnified party may cooperate in the defense at its expense using its own counsel; (iii) assisting the indemnifying party, at
the indemnifying party’s reasonable expense, in the investigation of, preparing for and defense of any such claim; and (iv) not compromising or settling such claim without the indemnifying party’s written consent. 

 

	10.	 LIMITATION OF LIABILITY 

To the extent permitted by applicable law: (a) in no event shall either party be liable under any legal theory for any special, indirect, consequential,
exemplary or incidental damages, however caused, arising out of or relating to this Agreement, even if such party has been advised of the possibility of such damages; and (b) in no event shall Consultant’s aggregate liability arising out
of or relating to this Agreement (regardless of the form of action giving rise to such liability, whether in contract, tort or otherwise) exceed the fees payable to Consultant hereunder; provided that the foregoing will not limit or restrict either
Party’s indemnification obligations under Section 9 or damages available for breach of Section 4 or 5. 

  
 7 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

	11.	 MISCELLANEOUS 

11.1 Assignment. No party shall assign, sell, transfer, delegate or otherwise dispose of, whether voluntarily or involuntarily,
by operation of law or otherwise, this Agreement or any or its rights or obligations under this Agreement; provided, however Customer and Limited may each assign, sell, transfer, delegate or otherwise dispose of this Agreement or any of its rights
and obligations hereunder as part of a merger, consolidation, corporate reorganization, sale of all or substantially all of its assets, sale of stock, change of name or like event. Any purported assignment, sale, transfer, delegation or other
disposition, except as permitted herein, shall be null and void. Subject to the foregoing, this Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors and permitted assigns. 

11.2 Notices. Any notice, request, demand or other communication required or permitted hereunder shall be in writing, shall
reference this Agreement and shall be deemed to be properly given: (a) when delivered personally; (b) when sent by facsimile, with written confirmation of receipt by the sending facsimile machine; (c) five (5) business days after
having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) two (2) business days after deposit with an express courier, with written confirmation of receipt. All notices shall be sent to the address set
forth on the signature page of this Agreement and to the notice of the person executing this Agreement (or to such other address or person as may be designated by a party by giving written notice to the other parties pursuant to this Section). 

11.3 Severability. If any provision of this Agreement, or the application thereof to any person, place or circumstance, shall be
held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, such provision shall be enforced to the maximum extent possible so as to effect the intent of the parties, or, if incapable of such enforcement, shall be
deemed to be deleted from this Agreement, and the remainder of this Agreement and such provisions as applied to other persons, places and circumstances shall remain in full force and effect. 

11.4 Waiver. The waiver by a party of a breach of or a default under any provision of this Agreement shall not be effective
unless in writing and shall not be construed as a waiver of any subsequent breach of or default under the same or any other provision of this Agreement, nor shall any delay or omission on the part of a party to exercise or avail itself of any right
or remedy that it has or may have hereunder operate as a waiver of any such right or remedy. 
 11.5 Governing Law. This
Agreement is to be construed in accordance with and governed by the internal laws of the State of California (as permitted by Section 1646.5 of the California Civil Code or any similar successor provision) without giving effect to any choice of
law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of California to the rights and duties of the parties. 

11.6 Relationship of Parties. This Agreement shall not be construed as creating an agency, partnership, joint venture or any
other form of association, for tax purposes or otherwise, between the parties; and the parties shall at all times be and remain independent contractors. Except as expressly agreed by the parties in writing, no party shall have any right or
authority, express or implied, to assume or create any obligation of any kind, or to make any representation or warranty, on behalf of any other party or to bind any other party in any respect whatsoever. No party shall have any obligation or duty
to any other party except as expressly and specifically set forth herein, and no such obligation or duty shall be implied by or inferred from this Agreement or the conduct of the parties hereunder. Consultant (and its employees, agents and
contractors) shall not be entitled to any of the benefits that Customer may make available to its employees, such as group health, life, disability or worker’s compensation insurance, profit-sharing or retirement benefits, and Customer shall
not withhold or make payments or contributions therefor or obtain 

  
 8 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
such protection for Consultant or its employees, contractors or agents. Consultant shall be solely responsible for all tax returns and payments required to be filed with or made to any federal,
state or local tax authority with respect to Consultant’s performance of services and receipt of fees under this Agreement. 

11.7 Headings. The headings used in this Agreement are for convenience only and shall not be considered in construing or
interpreting this Agreement. 
 11.8 Entire Agreement. This Agreement (including the Exhibits attached hereto, which are
incorporated herein by reference) is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior or contemporaneous proposals, discussions, negotiations, understandings,
promises, representations, conditions, communications and agreements, whether written or oral, between the parties with respect to such subject matter and all past courses of dealing or industry custom. 

[Signature Page Follows] 

  
 9 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 IN WITNESS WHEREOF, the parties have
caused this Agreement to be executed by their duly authorized representatives as of the Effective Date. 
  

									
	REPHARMATION INC.	 		 	SPARCBIO LLC
					
	By:	 	 /s/ David T. Hung
	 		 	By:	 	 /s/ Sarvajit Chakravarty

					
	Name:	 	David T. Hung	 		 	Name:	 	Sarvajit Chakravarty
	Title:	 	Founder, President & CEO	 		 	Title:	 	CEO
	Address:	 	[ADDRESS]	 		 	Address:	 	998 Tulip Court Sunnyvale, CA 94086

  

			
	REPHARMATION LIMITED
		
	By:	 	 /s/ David T. Hung

		
	Name:	 	David T. Hung
	Title:	 	Founder, President & CEO
	Address:	 	Clarendon House, 2 Church Street Hamilton HM 11, Bermuda

  
 10 

			
	SPARCBIO-RePharmation Inc. Collaboration Agreement	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 EXHIBIT A 

STATEMENT OF WORK (SOW #1) 

This Statement of Work is entered into as of January 21, 2019, by and between SPARCBIO LLC, a Delaware limited liability company
(“Consultant”), and RePharmation Inc., located at [ADDRESS] (“Customer”), pursuant to that certain Collaboration Agreement dated as of January 21, 2019 by and between Consultant, Customer and RePharmation
Limited (the “Agreement”). Any term not otherwise defined herein shall have the meaning set forth in the Agreement. 
 Services to be
Provided by Consultant 
  

	 	1.	 Consulting services to support Customer’s discovery and development activities relating to the
following programs (each of (a) – (g) and any additional program agreed upon pursuant to (h), a “Program” and collectively, the “Programs”): 

 

	 	a.	 Dual ligands of PARP and androgen receptors (PARP 2.0) 

 

	 	b.	 Dual ligands of PARP and estrogen receptors (PARP 3.0) 

 

	 	c.	 Androgen receptor (AR) ligands that are active in settings where third generation anti-androgens are
ineffective. These compounds may or may/not be dual inhibitors of the glucocorticoid receptor (GR) 

  

	 	d.	 Cyclin-Dependent Kinase (CDK) 4/6 inhibitors which are also inhibitors of other CDK’s including CDK 1,2
and 9 

  

	 	e.	 Wee1 Inhibitor 

  

	 	f.	 Adenosine (A2a/A2b) Antagonists 

 

	 	g.	 Bromodomain (BET/BRD) Inhibitors 

 

	 	h.	 Other programs as agreed by both parties 

 

	 	2.	 Activities for each Program described on the applicable budget for each Program (each, a “Program
Budget” and collectively, the “Budget”). The Program Budgets for Programs (a) – (g) above are attached hereto as Schedule A. The Parties shall agree in good faith on the Program Budget for any additional Programs
agreed upon by both parties pursuant to section (h) above, in each case that are consistent with the Program Budgets set forth in Schedule A. 

  

	 	3.	 Consultant will devote a minimum of [***] FTEs (where each FTE is equivalent to 160 hours of Services per
month) in the aggregate to performance of the Services in accordance with the activities described in the Budget for the Programs. If Programs (a) – (g) above do not fully utilize all [***] FTEs per month, then Consultant shall not unreasonably
withhold its agreement to conduct additional Programs requested by Customer to fully utilize such [***] FTEs to the extent such additional Programs can be serviced by such FTEs. 

 

	 	4.	 Requests for additional resources will be discussed with Customer at least 15 days prior to changes.

  

			
	REPHARMATION SPARCBIO COLLABORATION AGREEMENT EXHIBIT A-1	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 Compensation and Billing 

Customer will prepay amounts for the Services in accordance with the Agreement, and will pay Consultant’s fees and costs (including pass through costs
described below) to conduct the Services as provided in the Budget. Consultant will provide reasonably detailed invoices to Customer on a calendar quarterly basis for costs incurred in the preceding calendar quarter to conduct the Services in
accordance with the Budget. Consultant will invoice Customer for any Actual Costs incurred in a calendar quarter in excess of the amount pre-paid for that calendar quarter. Consultant will include with each
invoice reasonable documentation for any third party costs. 
 (1) Customer will pay Consultant a rate of $416,667.00 each month for Services
for managing aspects of the Programs, including all medicinal chemistry, biology, in-vitro ADME-PK, preliminary pre-clinical
DMPK/pharmacology and intellectual property related activities. 
 (2) Customer will pay Consultant for pass thru costs related to the
execution of scale up chemistry, chemical manufacturing, additional pre-clinical ADME, DMPK and pre-clinical pharmacology, toxicology and intellectual property related
activities. 
 Deliverables 
  

	 	(1)	 Synthesis, characterization and shipment of compounds for biological testing. 

 

	 	(2)	 Design, execution, periodic discussion and reporting of pre-clinical, PK-ADME, DMPK and clinical pharmacology studies. 

  

	 	(3)	 Communication, analysis and interpretation of medicinal chemistry, pharmacology,
PK-ADME and DMPK results. 

  

	 	(4)	 Additional deliverables to the extent set forth in a Budget. 

 

	 	(5)	 Written reports on scientific progress, including but not limited to, potential inventive ideas, data
collection, biological assay results, ADME-PK results and chemical synthesis progress. 

 Term

 The term of this Statement of Work will commence on the date set forth above and expire five (5) years thereafter, unless terminated earlier in
accordance with the Agreement. 
  

									
	REPHARMATION INC.	 		 	SPARCBIO LLC
					
	By:	 	 /s/ David T. Hung
	 		 	By:	 	 /s/ Sarvajit Chakravarty

					
	NAME:	 	 DAVID T. HUNG
	 		 	NAME:	 	 SARVAJIT CHAKRAVARTY

					
	TITLE:	 	 PRESIDENT & CEO
	 		 	TITLE:	 	 PRESIDENT & CEO

  

			
	REPHARMATION SPARCBIO COLLABORATION AGREEMENT EXHIBIT A-1	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 Schedule A 

Budget 
 [***] 

  

			
	REPHARMATION SPARCBIO COLLABORATION AGREEMENT EXHIBIT A-1	  	CONFIDENTIAL

 Certain information has been excluded from this agreement (indicated by “[***]”)
because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]